Business
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
HOUSTON, March 18, 2025--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024.
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"HOUSTON, March 18, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024.","length":344,"tagName":"p"},{"type":"text","content":"Corporate Highlights FY2024 to Date","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer’s disease (AD)","length":243,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD)","length":182,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced positive results from an investigator initiated double-blind study of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer’s Disease (AD) at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid. The study was titled, "A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer's Disease"","length":390,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Aligned with FDA on the non-clinical data needed to support the planned randomized, double-blind, placebo-controlled, Phase 2b trial of COYA-302 in patients with Amyotrophic Lateral Sclerosis (ALS)","length":197,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced expansion of pipeline- COYA 303; COYA 301 in combination with GLP-1 Receptor Agonist for treatment of inflammatory diseases and filing of new intellectual property portfolio for the combination","length":203,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1215,"olType":false},{"type":"text","content":"Financial Highlights FY 2024","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Raised $10.0M in a private placement of 1.38M shares of common st...